BioCentury
ARTICLE | Clinical News

J&J reports first-in-human data for mosaic vaccine

July 25, 2017 1:06 AM UTC

Johnson & Johnson (NYSE:JNJ) reported first-in-human data from the Phase Ib/IIa APPROACH study of several mosaic-based, prime-boost vaccine regimens to prevent HIV-1 infection. The company said the vaccine regimen appeared to be well-tolerated and elicited HIV-1 antibody responses in 100% of the 393 healthy volunteers.

The mosaic approach is intended to address many of the different HIV subtypes found globally, unlike previous approaches that focus on viruses from specific geographical areas. The vaccines incorporate immunogens created using genes from multiple HIV subtypes and are delivered via viral vectors. Brian Woodfall, J&J's global head of late development for infectious diseases and vaccines, told BioCentury that J&J is the only company using a mosaic-based strategy for HIV vaccines...